Literature DB >> 8313803

Hepatitis C virus genotypes are not responsible for development of serious liver disease.

M Yamada1, S Kakumu, K Yoshioka, Y Higashi, K Tanaka, T Ishikawa, M Takayanagi.   

Abstract

Although hepatitis C virus (HCV) is known to have at least four kinds of genotypes, no clear relationship has yet been established between the genotype and the severity of liver disease. Therefore, we determined HCV genotypes in sera of 251 Japanese patients with type C chronic liver disease, using polymerase chain reactions with six independent primers. One set of primers and a probe derived from 5'-noncoding region of HC-J1 was supposed to detect all four genotypes, while the other five were devised to detect each of the genotypes. Among the patients, the major genotype was type II (69%) and the second most common was type III (18%). Type IV was found in 7%, while none had type I genotype. There was no significant difference in the distribution of any genotype among different stages of liver disease, although the ratio of type II to type III tended to be higher in the group of cirrhosis and hepatocellular carcinoma than in the chronic hepatitis group (5.5 vs 3.0). The amounts of HCV RNA were significantly greater in patients with type II (P < 0.001) compared with those with types III and IV. However, HCV concentrations of each genotype were not associated with the disease status. These results suggest that HCV genotypes are unlikely to be responsible for the development of more serious liver disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313803     DOI: 10.1007/bf02090191

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

Review 1.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

2.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

3.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

4.  The 5'-terminal sequence of the hepatitis C virus genome.

Authors:  H Okamoto; S Okada; Y Sugiyama; S Yotsumoto; T Tanaka; H Yoshizawa; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Jpn J Exp Med       Date:  1990-06

5.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Hepatitis C-associated hepatocellular carcinoma.

Authors:  F Hasan; L J Jeffers; M De Medina; K R Reddy; T Parker; E R Schiff; M Houghton; Q L Choo; G Kuo
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

7.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Hepatitis C viremia in patients with hepatitis C virus infection.

Authors:  A S Lok; R Cheung; R Chan; V Liu
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425

10.  Clinical backgrounds of the patients having different types of hepatitis C virus genomes.

Authors:  N Takada; S Takase; N Enomoto; A Takada; T Date
Journal:  J Hepatol       Date:  1992-01       Impact factor: 25.083

View more
  27 in total

Review 1.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Clinical sequelae of hepatitis C acquired from injection drug use.

Authors:  M J Tong; N S el-Farra
Journal:  West J Med       Date:  1996-05

3.  Clinical relevance of hepatitis C virus genotypes.

Authors:  P Simmonds
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 4.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

6.  Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion.

Authors:  Yan-Feng Pan; Yan Zheng; Tao Qin; Lei Feng; Qian Zhang; Xiao-Gong Ping; Yan-Ting Pan; Xiao-Ping Wang; Li Bai; Hua-Hua Li
Journal:  Exp Ther Med       Date:  2016-10-11       Impact factor: 2.447

7.  Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regions.

Authors:  P Toniutto; M Pirisi; S G Tisminetzky; C Fabris; E Chinellato; M Gerotto; E Falleti; P Ferroni; T Lombardelli; E Bartoli; F Baralle
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

8.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.

Authors:  E Villa; P Buttafoco; A Merighi; A Grottola; I Ferretti; A Ferrari; F Callea; P Trande; A M Rebecchi; F Manenti
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

Review 10.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.